Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL996518 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL573837 | 0.92 | ALDH1A1 (0.79) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL996510 | 0.90 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRDNM1MEN1 | |
| SCHEMBL10182894 | 0.90 | ALDH1A1 (0.68) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL9950032 | 0.89 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL642452 | 0.89 | ALDH1A1 (0.59) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL8568383 | 0.88 | ALDH1A1 (0.60) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL17483173 | 0.87 | ALDH1A1 (0.65) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL23917937 | 0.86 | ALDH1A1 (0.71) | ALDH1A1TDP1CYP3A4TSHRDNM1 | |
| SCHEMBL18844173 | 0.86 | ALDH1A1 (0.71) | ALDH1A1TDP1CYP3A4TSHRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105705585-B | Additive for improved impact strength and resin combination flexible | 埃瑟克斯化学有限责任公司 | 2018-11-09 | — | — | CN | claimed |
| CN-106433536-B | A kind of double cured epoxy resin vinyl ester resin adhesive for underground engineering fracture plugging reinforcement | 湖南固特邦土木技术发展有限公司 | 2017-12-22 | — | — | CN | claimed |
| CN-106433536-A | Dual-curing epoxy resin-vinyl ester resin adhesive used for leaking stoppage and reinforcement of underground engineering fracture | 湖南固特邦土木技术发展有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-103814057-B | Henzylate polyamine curing agent | 气体产品与化学公司 | 2016-08-17 | — | — | CN | claimed |
| CN-105705585-A | Additives to resin compositions for improved impact strength and flexibility | 埃瑟克斯化学有限责任公司 | 2016-06-22 | — | — | CN | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-104997762-B | Oral delivery drug comprising MGBG and the method for treating disease | 帕萨罗杰卡有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109432073-A | Purposes of the MGBG in the drug that preparation treats or prevents progressive MS and its progress | 帕萨罗杰卡有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-1373185-A4 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6963010-B2 | Anticancer agents; osteoporosis; autoimmune disease | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| CN-1511137-A | Hydrophobic polyamine analogs and methods of use thereof | 麦迪凯斯特治疗学股份有限公司 | 2004-07-07 | — | — | CN | disclosed |
| EP-1373185-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | Mediquest Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2002053519-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | ALDH1A1 2904/4885TDP1 695/4885CYP3A4 4767/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | ALDH1A1 2904/4885TDP1 695/4885CYP3A4 4767/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | ALDH1A1 1242/4885TDP1 1487/4885CYP3A4 3788/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | ALDH1A1 2637/4885TDP1 743/4885CYP3A4 3950/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | ALDH1A1 2637/4885TDP1 743/4885CYP3A4 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.